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Purpose: The aim of this preliminary study was to determine
the possible relationship between alkaline phosphatase (ALP)
levels in the gingival crevicular fluid (GCF) and periodontal
disease in men with hypergonadotropic hypogonadism (HH).
Materials and Methods: A total of 41 patients were divided
into four groups. 9 with HH and periodontitis (P/HH), 11
with HH and gingivitis (G/HH), 12 with systemically healthy
and periodontally healthy (H/C) and 9 with systemically
healthy and periodontitis (P/C). The clinical evaluation of
patients was based on the following parameters; the plaque
index (PI), gingival index (GI), probing depths (PD) and
attachment level (AL). The levels of ALP in the GCF were
measured by enzyme-linked immunosorbent assay (ELISA).
Results: No significant difference could be detected in the
mean clinical parameter data between the P/HH and P/C
groups (p > 0.05). The periodontitis patients in both groups
(P/C and P/HH) had higher mean probing depths than the
H/C and G/HH patients (p < 0.001). The concentrations and
total amounts of ALP in the GCF were significantly higher
in both periodontitis groups compared to healthy and
gingivitis groups (p < 0.01). The serum ALP levels were
significantly higher in the P/HH group when compared to the
other groups (p < 0.001). Conclusion: The findings of this
study suggested that HH could be implicated as a
contributing factor to the progress of periodontal disease.
Key Words: Hypogonadism, alkaline phosphatase, gingival
crevicular fluid, periodontal disease
INTRODUCTION
The supporting tissues of the periodontium
are vulnerable to the physiological variations in
the levels of circulating steroid hormones in both
males and females. Several pathways exist for
estrogens and progestins, as well as androgens
to exacerbate gingival inflammation and promote
periodontal disease.
1 Periodontal alveolar bone
loss could be due to systemic osteoporosis, but
more so to periodontal disease.
2 Several authors
have suggested that the mandibular bone
density may be indicative of the systemic bone
density.
3,4 There has been increasing interest in
the relationship between systemic osteoporosis,
oral bone loss, tooth loss and risk factors for
these conditions. Changes in bone metabolism
and decrease in the bone mineral component
(BMC) of the skeleton especially the jaw may be
a stimulating factor of periodontal disease.
3,4 This
relationship is difficult to establish, as the results
may easily be confounded by other factors, such
as gender, hormone intake, smoking, race and
age.
5
It has been speculated that osteopenia/osteo-
porosis plays a role in the progression of oral
bone loss following the menopause
3,6,7 Although
osteoporosis is more common in women, it also
occurs in men with hypogonadism of prepubertal
onset.
8,9 Hypergonadotropic hypogonadism (pri-
mary hypogonadism) is characterized by a low
testosterone level, high levels of gonadotropins
and elevated luteinizing hormone (LH) and follicle-
stimulating hormone (FSH).
10 Hypogonadism is a
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well-established cause of osteoporosis in men and
hypogonadal osteoporosis is associated with
increased bone resorption and decreased minerali-
zation. The pathogenesis of bone loss in hypogo-
nadal men remains uncertain, although it has
been suggested that it may be due to the direct
effects of androgen, estrogen deficiency, malab-
sorption of calcium and reduced circulating
calcitonin levels.
8
Recently, biochemical markers for bone metabo-
lism have been developed and are expected to
reflect minor changes of bone turnover.
11 The rate
of bone formation or degradation can be assessed
either by measuring an enzymatic activity of the
osteoblastic or osteoclastic cells, such as that of
the alkaline and acid phosphatase or by
measuring components of the bone matrix that
are released into circulation during formation or
resorption.
12 The alkaline phosphatase (ALP)
activity is the most commonly used marker of
bone formation. ALP has been found in various
periodontal tissues
13,14 and its serum level can be
used as an indicator of bone formation.
12 Studies
have revealed that ALP can often be measured in
the gingival crevicular fluid (GCF) to examine its
relations to periodontal conditions and disease
activity.
15-18 Ishikawa and Cimasoni
19 demon-
strated that enzyme levels in the GCF were 3
times higher than those in the serum and
significant correlation was shown between the
ALP concentration in the GCF and the pocket
depth. Binder et al.
15 performed a longitudinal
study of 8 patients and demonstrated a positive
relation of the GCF alkaline phosphatase concen-
tration with attachment loss.
To date, the studies have focused on the rela-
tionship between periodontal disease and osteo-
porosis in relation to the hormonal changes in
women.
3,6,20 However, there have been a limited
number of studies that show the effects of the
hormonal changes in men on periodontal tissues.
1
However, there is no information concerning the
periodontal condition in men with hypergonado-
tropic hypogonadism. The aim of this preliminary
study was to determine the possible relationship
between ALP levels in the GCF and periodontal
disease in men with hypergonadotropic hypo-
gonadism.
MATERIALS AND METHODS
Study population
A total of 41 patients, divided into 4 groups,
participated in this study. Twenty males with HH
(18 to 20 years old; mean age 20.81 ± 1.33 years)
were derived from an army population at the
Gulhane Military Medical Academy (GATA). The
patients in need of periodontal treatment were
referred from the Endocrinology Department to
the Periodontology Department. The study was
approved by the Ethical Committee of the GATA,
Sciences of Dentistry, Ankara, Turkey. The in-
formed consent of all subjects was obtained and
all procedures were fully explained before the
study. After clinical and radiographic examina-
tions, 9 males with gingivitis (G), with a mean
age: 20.45 ± 0.20 years and 11 males with perio-
dontitis (P), with a mean age: 21.44 ± 0.29 years,
were selected from the HH patients.
There were 21 volunteers in the systemically
healthy control (C) group (9 males with perio-
dontitis (P), with a mean age: 20.33 ± 0.44 years
and 12 males with periodontally healthy (H),with
a mean age: 21.17 ± 0.36 years) were drawn from
staff at the GATA. The periodontitis patients were
selected based on the radiographical evidence of
bone loss and the presence of four or more sites
with pocket depths > 5 mm. The gingivitis patients
had no evidence of bone loss but varying degrees
of gingival inflammation. The periodontally
healthy individuals were selected on the basis of
no radiographic evidence of alveolar bone and
attachment losses, with no probing depths greater
than 3 mm and no significant bleeding on pro-
bing. The subjects had not received professional
teeth cleaning or systemic medication, including
androgen substitution drugs, during the 6 months
prior to the study.
Periodontal examination
The clinical evaluation of patients was based on
the following parameters: the plaque index (PI),
21
gingival index (GI),
22 probing depths (PD) and
attachment level (AL). All parameters were mea-
sured with a Williams probe calibrated in milli-
meters. All clinical parameters were performed onAlkaline Phosphatase Levels in Men with Hypogonadism
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6 points per tooth (mesio-mid and disto-buccal;
mesio-mid and disto-lingual). Clinical examina-
tions were carried out by the same investigator.
GCF sampling and processing
In order to avoid blood contamination and
possible stimulation of GCF flow during the
clinical measurements, the GCF samples were
collected before any other clinical recordings. The
GCF sample of each subject was collected from
the maxillary anterior area. Prior to GCF collec-
tion, the supragingival plaque was removed. The
sample site was gently dried using an air syringe
and isolated from saliva with cotton rolls. The
GCF was collected using Whatman chromato-
graphy paper (2 × 8mm). Paper strips with a notch,
were inserted 1 mm into the gingival sulcus and
left in place for 30 seconds.
23 Care was taken to
avoid any mechanical injury. Strips contaminated
with blood or exudate were discarded. The amount
of GCF on the strips was measured by weighing
the accumulated fluid. The paper strips were
placed into coded sealed plastic microcentrifuge
tubes. To determine the amount of GCF, an
electronic balance (Precisa 62 A, Precisa Instruments
AG, CH-Dietikan, Zürich, Switzerland) was used
for weighing the paper strips before and imme-
diately after the collection. The strips were stored
at -70 until assayed. The mass (mg) of the fluid
on each strip was converted to a volume in
milliliters (mL) by assuming a GCF density of 1.
24
GCF and serum enzyme-linked immunosorbent
assay (ELISA) analysis for ALP
The levels of ALP in the GCF were measured
using an ELISA kit (Biomereux, SA, Marcy
I'Etoile, France) according to the manufacturer's
instructions. The ALP levels in the GCF samples
were determined from samples on filter paper
strips placed in 96-well microtiter plates. Two
hundred and fifty μl of AMP buffer (pH 10.5 in
amino-2 methyle-2 propanol-1 buffer) were
dispensed into each well and the strips removed
after soaking for 90 min at room temperature.
Fifty μL of 0.95 mM p-nitro phenylphosphate in
buffer AMP was added to each well and the plate
incubated for 45 min. Fifty L of 1 M NaOH were μ
added. Optical density readings of each well were
measured at 405 nm. by using ELISA reader (Bio-
Tek Instrument inc. Vinooski, VT, Vermont, USA).
The final results were expressed as corrected
optical densities or enzyme units, where 1 unit =
1 μmol p-nitro phenylphosphate converted to p-
nitro phenol plus inorganic phosphate per min at
the pH and temperature indicated for each enzyme.
Serum samples were assayed using the protocol
described for the GCF. The optical density was
measured using a Technicon Dax-48 analyzer
(Bayer Diagnostica, Leverkusen, Germany).
Statistical analysis
The mean values and standard errors of the
measured parameters were assessed by a one-way
analysis of variance (ANOVA). The significant
differences were examined using the Duncan test.
The correlations between the GCF enzymes and
clinical parameters in all groups were examined
by a Pearson correlation analysis. All calculations
were undertaken using a statistical software
package (SPSS v.10.0 Inc., Chicago, IL, USA).
RESULTS
The biochemical parameters for diagnostic
evaluation of the Hypergonadotropic hypogo-
nadism patients are presented in Table 1.
The clinical parameters data (mean ± SE) for all
groups are presented in Table 2. When consi-
dering the mean age, there were no differences
among the groups. No significant difference could
be detected in the mean clinical parameter data
between the P/HH and P/C groups (p > 0.05).
When the PI, GI, PD and AL scores were consi-
dered, the periodontally healthy control group
(H/C) exhibited significant differences compared
to all the other periodontitis groups (p < 0.001).
The periodontitis patients in both groups (P/C
and P/HH) had higher mean probing depths than
the H/C and G/HH patients (p < 0.001). There
was no difference between the pocket depths of
the G/HH and H/C patients.
The mean GCF and serum ALP levels and GCF
volume are summarized in Table 3. Periodontitis
patients (P/HH and P/C) demonstrated signifiTable 2. Clinical Parameters of the Study Groups
Control (C) Hypergonadotropic hypogonadism (HH)
p Healthy
(H\C)
1
Periodontitis
(P\C)
2
Gingivitis
(G\HH)
3
Periodontitis
(P\HH)
4
Age 21.17 ± 0.36 20.33 ± 0.44 20.45 ± 0.20 21.44 ± 0.29 > 0.05
PLI 0.60 ± 0.04 1.60 ± 0.15 0.94 ± 0.03 1.37 ± 0.14 < 0.001 (1 and 2)
< 0.001 (1 and 3)
< 0.001 (1 and 4)
0.001 (2 and 3)
0.002 (3 and 4)
GI 0.54 ± 0.04 1.41 ± 0.12 0.85 ± 0.01 1.37 ± 0.13 < 0.001 (1 and 2)
0.004 (1 and 3)
0.002 (1 and 4)
0.004 (2 and 3)
0.005 (3 and 4)
PD 2.04 ± 0.10 3.10 ± 0.10 2.25 ± 0.03 3.20 ± 0.11 < 0.001 (1 and 2)
< 0.001 (1 and 4)
< 0.001 (2 and 3)
0.005 (3 and 4)
AL 2.10 ± 0.11 3.39 ± 0.08 2.68 ± 0.06 3.57 ± 0.12 < 0.001 (1 and 2)
0.002 (1 and 3)
< 0.001 (1 and 4)
< 0.001 (2 and 3)
0.004 (3 and 4)
All values are expressed as mean ± standard error.
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Table 1. Biochemical Parameters for Diagnostic Evaluation of Hypergonadotropic Hypogonadism Patients
Normal range Gingivitis HH Periodontitis HH
FSH (mIU/mL) 1.5 - 9.7 84.48 ± 24.69 63.16 ± 28.98
LH (mIU/mL) 1.5 - 9.3 64.43 ± 40.32 78.80 ± 37.57
Ttest (ng/dL) 241 - 827 16.46 ± 22.26 45.71 ± 27.15
Ftest (pg/mL) 8.7 - 54.7 4.08 ± 2.87 3.33 ± 2.52
DHEA-S (microgr/dL) 80 - 560 140 ± 72.14 165.33 ± 106.28
EE2 (pg/mL) 0.52 15.21 ± 14.41 8.55 ± 6.8
SHBG (nmol/L) 13 - 71 25.54 ± 12.97 36.77 ± 29.57
Hidroxyprolin (mg/24 hrs) 2 - 17 8.62 ± 3.48 5.35 ± 1.72
Ca (mg/day) 8.5 - 10.5 8.89 ± 0.53 8.90 ± 0.41
P (mg/day) 2.7 - 4.5 4.89 ± 1.34 4.18 ± 0.73
FSH, follicle-stimulating hormone; LH, luteinizing hormone; ttest, total testosterone; Ftest, free testosterone;
DHEA-S, dihydroepiandrosterodine-sulphate; EE2, estradiol; SHBG, sex hormone-binding globulin.Alkaline Phosphatase Levels in Men with Hypogonadism
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cantly increased GCF volumes compared to
healthy (H/C) and gingivitis (G/HH) patients (p
< 0.01). In the P/HH group, the mean total ALP
level was higher than in the H/C and G/HH
groups. The difference was found to be statistically
significant (p < 0.01), while that between the
P/HH and P/C groups was not (p > 0.05). The
healthy control group (H/C) presented lower ALP
concentrations than the other patient groups. The
differences between the H/C and P/C group and
H/C and P/HH group were found to be statisti-
cally significant (p < 0.01). The P/HH group
showed higher serum ALP than the other groups
which were statistically significant (p < 0.001).
Table 4 shows the correlations between the
clinical parameters and the GCF enzyme activity
in all groups. In the P/HH group, the total ALP
activity and ALP concentration presented negative
and non-significant correlations with PI and GI
but a positive correlation with the mean PD (p >
0.05). In the P/C group, the total ALP activity and
ALP concentration exhibited weak-positive cor-
relations with PI, GI and AL but strong-positive
and significant correlations with PD (p < 0.05).
There was a strong negative correlation between
the GCF volume and GI scores in the P/HH
group (p < 0.05).
DISCUSSION
Hypogonadism is one of the most frequent
causes of osteoporosis in men.
25,26 The diagnosis of
hypogonadism may not always be clinically ap-
parent and the routine measurements consider all
definable causes for osteoporosis in men.
27 In the
present study, the patients were diagnosed ran-
domly from an army population during routine
laboratory testing. The diagnostic biochemical
evaluations for osteoporosis in hypogonadism
patients are presented Table 1. Low serum testos-
terone levels were seen in our hypogonadism
patients and it's insufficiency is well known as a
major risk factor for male osteoporosis.
8,25
ALP has often been measured in the GCF to
examine relations to periodontal conditions.
14 The
aim of this preliminary study was to assess the
relationship between clinical periodontal condi-
tions and alkaline phosphatase levels in men with
hypergonadotropic hypogonadism.
No published report on the GCF ALP level in
hypergonadotropic hypogonadism patients could
be found, so our data could not be compared with
similar studies. In the present study, no statisti-
cally significant differences could be detected
between the two periodontitis groups (P/HH-
P/C) with any of the clinically parameters. These
Table 3. GCF Values of ALP in the Hypergonadotropic Hypogonadism and Control Groups
Control group (C)
Hypergonadotropic
hypogonadism (HH)
p
Healthy
(H\C)
1
Periodontitis
(P\C)
2
Gingivitis
(G\HH)
3
Periodontitis
(P\HH)
4
GCF volume 12.59 ± 1.32 18.89 ± 1.16 13.11 ± 1.46 19.00 ± 1.84 0.006 (1 and 2)
0.004 (1 and 4)
0.004 (2 and 3)
0.002 (3 and 4)
GCF ALP concentration (U\ L) μ 139.25 ± 22.09 350.78 ± 78.92 207.18 ± 31.14 323.00 ± 49.45 0.008 (1 and 2)
0.003 (1 and 4)
0.006 (2 and 3)
GCF ALP total (U\site) 12.17 ± 1.85 18.11 ± 3.52 11.73 ± 1.73 26.67 ± 4.93 0.008 (1 and 4)
0.005 (3 and 4)
Serum ALP 74.50 ± 17.96 68.44 ± 4.91 96.44 ± 17.51 160.73 ± 10.85 < 0.001 (1 and 4)
< 0.001 (2 and 4)
< 0.001 (3 and 4)
All values are expressed as mean ± standard error.Berrin Ünsal, et al.
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results indicate that the degree of periodontal
disease was similar in both groups. In the present
study the level of supragingival plaque accumula-
tion was found to be significantly different
between the P/HH and G/HH, and the H/C and
P/C groups. There is no doubt that bacterial
plaque is a major cause of the initiation and
maintenance of gingival inflammation.
Ishikawa and Cimasoni
19 reported that ALP
levels in the GCF harvested from periodontitis
correlated positively and significantly with the
pocket depth and the mean percentage of bone
loss. Our findings are in accordance with those of
previous studies.
15,16,19 Total amounts and concen-
trations of GCF ALP were significantly and
positively correlated with the probing depth in
our P/C group. The present study also supports
the findings of previous studies that reported
increased GCF ALP levels in the presence of per-
iodontal destruction.
16 Ishikawa and Cimasoni
19
demonstrated that the GCF ALP levels were
significantly higher from those in the serum. In
the present study, the ALP levels in the GCF from
both the patients and control groups were found
to be higher than those measured in the serum,
which is contradictory to previous findings that
indicate the local production of significant
amounts of ALP by periodontal tissues or within
the periodontal pocket. In addition the ALP
within the GCF is probably a mixture of that from
the serum, host tissue, polymorphonuclear leuko-
cytes (PMNL) and bacterial origin.
15
While periodontal disease is a local disease,
hypergonadotropic hypogonadism is a systemic
disease. Bone loss is a common feature of both
diseases. Biochemical markers, including the ALP,
have also been associated with bone loss from
periodontal disease. We could suggest that
systemic bone loss in these patients may lead to
periodontitis with increased ALP levels.
Both the concentrations and total amounts of
ALP were significantly higher in the periodontitis
groups compared to the healthy and gingivitis
groups (Table 3). However the mean total GCF
ALP in the P/HH group was higher than that in
the P/C group, but no significant difference was
Table 4. Correlation Between Clinical Parameters and ALP Levels
GCF volume
r
Total ALP
r
ALP concentration
r
H\C
PLI
GI
PD
AL
- 0.203
- 0.410
0.284
0.323
0.282
- 0.073
0.275
0.170
0.009
- 0.402
0.467
0.370
P\C
PLI
GI
PD
AL
0.645
- 0.083
0.505
0.391
0.301
0.434
0.745*
0.659
0.408
0.338
0.764*
0.660
G\HH
PLI
GI
PD
AL
- 0.127
0.495
0.390
0.096
- 0.126
0.218
- 0.227
- 0.121
- 0.291
- 0.150
0.074
- 0.057
P\HH
PLI
GI
PD
AL
- 0.134
- 0.773*
- 0.266
- 0.524
- 0.004
0.202
0.067
- 0.005
- 0.160
0.011
0.001
- 0.175
*p < 0.05.
r, pearson correlation coefficient.Alkaline Phosphatase Levels in Men with Hypogonadism
Yonsei Med J Vol. 49, No. 1, 2008
found between the two periodontitis groups. The
total amount in the GCF correlated better rather
than the enzyme concentrations.
28 It is possible to
suggest for the ALP, the data presented as total
activity are more precise in reflecting the existing
clinical periodontal status compared to the con-
centration expressed. The concentration of GCF
ALP is dependent upon the GCF volume. The
GCF volume is also influenced by many other
factors such as the flow rate, gingival trauma and
repeated sampling.
29,30 It is logical to expect that
the total level of this enzyme in gingival fluid will
correlate better with the disease than the enzyme
concentrations, as in the study of Chapple et al.
17
According to our data, It has been shown that the
GCF volume increases in the order healthy, gingi-
vitis and periodontitis patients and reflects the
presence of gingival inflammation.
The findings of this study suggest a role of HH
in periodontal disease could be implicated as a
contributing factor to the progress of periodontal
disease. However, no data in the medical litera-
ture suggest an interaction between periodontal
destruction and HH in men. Therefore additional
studies are needed to define the relationship be-
tween hypergonadotropic hypogonadism in men,
alveolar bone loss and periodontal disease.
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